MedPath

UVAX BIO, LLC

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Early Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)β€’ Click on a phase to view related trials

Early Phase 1
1 (100.0%)

Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.

Early Phase 1
Completed
Conditions
HIV Infections
AIDS/HIV - RelatedDisease Associated With AIDS
Vaccine-Preventable Diseases
Interventions
First Posted Date
2024-08-07
Last Posted Date
2025-05-23
Lead Sponsor
Uvax Bio LLC
Target Recruit Count
34
Registration Number
NCT06541093
Locations
πŸ‡¦πŸ‡Ί

Nucleus Network Melbourne, Melbourne, Victoria, Australia

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.